Gemseki

Gemseki is a Tokyo-based corporate venture capital firm founded in 2017 that specializes in the development and commercialization of drug candidates. The company operates a Drug Candidate Marketplace platform, which connects organizations looking to introduce or license their drug candidates with those interested in acquiring knowledge and rights to these candidates for further development. By facilitating these connections, Gemseki aims to optimize the utilization of untapped drug candidates, thereby fostering the creation of valuable new pharmaceuticals. In addition to its marketplace activities, the firm also engages in venture capital investments focused on drug discovery initiatives.

Haolin Sung

Region Director, Asia

3 past transactions

Cellusion

Venture Round in 2022

Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Curreio

Venture Round in 2021

Curreio develops contract business for structural analysis using cryo-electron microscopy.

Cardio Intelligence

Seed Round in 2021

Cardio Intelligence Inc. engages in the research, development, and sale of AI electrocardiographic diagnosis systems. The company’s automated AI diagnostic system supports healthcare professionals in the treatment and prevention of heart diseases. It also offers software development, patent licensing, medical equipment lending and repairing, and contract services for pharmaceutical companies. Cardio Intelligence Inc. was founded in 2019 and is based in Tokyo, Japan.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.